ReviewCurrent rheumatology reports2012
Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?
William StohlPubMed ↗Publisher ↗
No numbers read from the abstract.
20 papers cite it
this paperpooled itcites it